3rd March 2020 Author: Paul Carton
Qiagen Streamlines Covid-19 Molecular Workflow with Rapid Swab Analyzer
Qiagen's all-in-one analyzer for respiratory infections has been adapted to allow for Covid-19 testing. A technician simply loads a clinical sample (such as a swab) into a single-use cartridge and places it in the QIAstat-Dx analyzer and receives a result in approximately one hour. The QIAstat-DX Respiratory Panel 2019-nCoV test kit is currently under evaluation in four hospitals in China and at the Bichat-Claude Bernard Hospital in Paris, after it passed the initial evaluation there.
The assay, which can differentiate SARS-CoV-2 from 21 other respiratory pathogens, targets the ORF1b gene (RNA-dependent polymerase) and the E-gene (envelope protein).
QIAGEN will apply for emergency authorization for the marketing of the new panel from the U.S., the Korean KCDC/MFDS, and FDA and China's National Medical Products Administration (NMPA); the panel is planned to have CE-IVD marking in Europe and other markets.
Related news: Qiagen N.V has accepted Thermo Fisher's offer to acquire the molecular diagnostics company. Pricing at the time of the announcement put Qiagen at $11.5 billion. Qiagen generated $1.53 billion in 2019, and this acquisition will expand Thermo Fisher's portfolio to include infectious disease testing.
Date Published: 3rd March 2020
Source article link: View